Vol.

No.

October 03, 2014Oct 03, 2014

Free

DOWNLOAD THE PDF

Cover Story

Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

A move by Genentech has eliminated discounts and rebates hospitals receive when they purchase three of the company's top-selling infused cancer drugs.

Conversation with The Cancer Letter

"These are Life-Saving Drugs. I'm Not Going To Stop Treating Patients, Right?"

By Paul Goldberg

Fake Avastin, Paid for by Medicare, Administered to U.S. Patients

By Will Craft

Gonzalez-Angulo To Serve 10 Years In Poisoning Case

By Leonard Zwelling

FDA Publishes Two Guidances for Lab-Developed Tests

By Matthew Bin Han Ong

Groups Push For CMS Coverage For LDCT Lung Screening

By Matthew Bin Han Ong

In Brief

Platanias Appointed Director Of Lurie Cancer Center

Karmanos Cancer Institute and Wayne State sign new affiliation agreement

Robert Miller named medical director of ASCO Institute of Quality

MD Anderson Cancer Center receives $10 million from ExxonMobil

Jan Egberts appointed CEO of Agendia Inc.

Memorial Sloan Kettering to open largest suburban location

CancerCare receives $1.5 million from Susan G. Komen

Funding Opportunities

NYC-Based Research Alliance Offering $200,000 per Year for Young Investigators

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues